Literature DB >> 11728545

HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers.

P Sonnenberg1, J Murray, J R Glynn, S Shearer, B Kambashi, P Godfrey-Faussett.   

Abstract

BACKGROUND: The proportion of recurrent tuberculosis cases attributable to relapse or reinfection and the risk factors associated with these different mechanisms are poorly understood. We followed up a cohort of 326 South African mineworkers, who had successfully completed treatment for pulmonary tuberculosis in 1995, to determine the rate and mechanisms of recurrence.
METHODS: Patients were examined 3 and 6 months after cure, and then were monitored by the routine tuberculosis surveillance system until December, 1998. IS6110 DNA fingerprints from initial and subsequent episodes of tuberculosis were compared to determine whether recurrence was due to relapse or reinfection All patients gave consent for HIV-1 testing.
FINDINGS: During follow-up (median 25.1 months, IQR 13.2-33.4), 65 patients (20%) had a recurrent episode of tuberculosis, a recurrence rate of 10.3 episodes per 100 person-years at risk (PYAR)-16.0 per 100 pyar in HIV-1-positive patients and 6.4 per 100 pyar in HIV-1-negative patients. Paired DNA fingerprints were available in 39 of 65 recurrences: 25 pairs were identical (relapse) and 14 were different (reinfection). 93% (13/14) of recurrences within the first 6 months were attributable to relapse compared with 48% (12/25) of later recurrences. HIV-1 infection was a risk factor for recurrence (hazard ratio 2.4, 95% CI 1.5-4.0), due to its strong association with disease caused by reinfection (18.7 2.4-143), but not relapse (0.58; 0.24-1.4). Residual cavitation and increasing years of employment at the mine were risk factors for relapse.
INTERPRETATION: In a setting with a high risk of tuberculous infection, HIV-1 increases the risk of recurrent tuberculosis because of an increased risk of reinfection. Interventions to prevent recurrent disease, such as lifelong chemoprophylaxis in HIV-1-positive tuberculosis patients, should be further assessed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728545     DOI: 10.1016/S0140-6736(01)06712-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  139 in total

1.  Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.

Authors:  Yuri F van der Heijden; Fareed Abdullah; Bruno B Andrade; Jason R Andrews; Devasahayam J Christopher; Julio Croda; Heather Ewing; David W Haas; Mark Hatherill; C Robert Horsburgh; Vidya Mave; Helder I Nakaya; Valeria Rolla; Sudha Srinivasan; Retna Indah Sugiyono; Cesar Ugarte-Gil; Carol Hamilton
Journal:  Tuberculosis (Edinb)       Date:  2018-10-01       Impact factor: 3.131

2.  Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.

Authors:  Ted Cohen; Marc Lipsitch; Rochelle P Walensky; Megan Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

3.  How host heterogeneity governs tuberculosis reinfection?

Authors:  M Gabriela M Gomes; Ricardo Aguas; João S Lopes; Marta C Nunes; Carlota Rebelo; Paula Rodrigues; Claudio J Struchiner
Journal:  Proc Biol Sci       Date:  2012-02-22       Impact factor: 5.349

4.  Microevolution of Mycobacterium tuberculosis in a tuberculosis patient.

Authors:  Sahal A M Al-Hajoj; Onno Akkerman; Ida Parwati; Saad al-Gamdi; Zeaur Rahim; Dick van Soolingen; Jakko van Ingen; Philip Supply; Adri G M van der Zanden
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

5.  Mining and risk of tuberculosis in sub-Saharan Africa.

Authors:  David Stuckler; Sanjay Basu; Martin McKee; Mark Lurie
Journal:  Am J Public Health       Date:  2010-06-01       Impact factor: 9.308

6.  High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions.

Authors:  Florian M Marx; Sian Floyd; Helen Ayles; Peter Godfrey-Faussett; Nulda Beyers; Ted Cohen
Journal:  Eur Respir J       Date:  2016-07-07       Impact factor: 16.671

7.  Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?

Authors:  S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood
Journal:  Int J Tuberc Lung Dis       Date:  2011-05       Impact factor: 2.373

8.  23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects.

Authors:  Huichang Huang; Xiaohua Qian; Rong Pan; Ling Shen; Shanshan Liang; Feifei Wang; Peng Zhang; Hongbo Shen; Zheng W Chen
Journal:  Clin Immunol       Date:  2018-05-09       Impact factor: 3.969

Review 9.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

Review 10.  A systematic review of published literature describing factors associated with tuberculosis recurrence in people living with HIV in Africa.

Authors:  Yoshan Moodley; Kumeren Govender
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.